What is Positron?
Founded in 1983 and headquartered in Westmont, Positron Corporation operates at the intersection of advanced medical diagnostics and radiopharmaceutical production. The company is primarily recognized for its Attrius system, a sophisticated cardiac PET imaging platform designed to enhance the precision of heart disease diagnosis while optimizing clinical cost-efficiency. Beyond hardware, Positron maintains a vertically integrated business model that encompasses clinical support services, automated radiopharmaceutical systems, and the complex processing of radioisotopes such as Sr-82. By managing both the imaging technology and the supply chain for essential medical isotopes, Positron occupies a unique niche in the United States healthcare market, providing essential tools that enable providers to improve patient outcomes through high-fidelity molecular imaging.
How much funding has Positron raised?
Positron has raised a total of $33.6M across 4 funding rounds:
Debt
$66K
Multiple Rounds
$33.5M
Debt (2021): $66K with participation from PPP
Angel/Seed (2025): $23.5M led by Flume Ventures, Atreides Management, and Valor Equity Partners
Share Placement (2025): $8M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Key Investors in Positron
Flume Ventures
Flume Ventures is a network of seasoned operators and founders dedicated to partnering with visionary entrepreneurs to scale bold ideas through strategic mentorship and community support.
Atreides Management
Headquartered in Boston, Atreides Management specializes in long-term capital deployment for technology and consumer-focused enterprises across both public and private markets.
Valor Equity Partners
Established in 2001 and based in Chicago, Valor Equity Partners is a financial services firm that provides strategic investment and operational support to growing businesses.
What's next for Positron?
With the successful closure of this recent financing round, Positron is well-positioned to accelerate its operational roadmap. The strategic allocation of these funds is expected to focus on the optimization of Sr-82 supply chains, particularly through the recycling of spent generators and the processing of proton-irradiated target materials. Furthermore, the company is likely to leverage this capital to bolster its market penetration, ensuring that its Attrius system remains the standard for cardiac PET imaging. As the firm transitions into this next phase of growth, stakeholders will be monitoring its ability to scale production capabilities and maintain its competitive advantage in the high-barrier-to-entry nuclear medicine sector. The focus remains on long-term value creation through technological innovation and the strengthening of its domestic and international supply partnerships.
See full Positron company page
